SAN FRANCISCO, Sept. 19, 2016 — Sutro Biopharma Inc. today announced that it has presented findings from two studies of investigational antibody drug conjugates, or ADCs, that it developed to target CD74, a protein highly expressed in hematologic malignancies. The ADCs demonstrated efficient cell killing in multiple malignant B-cell lines and suppressed tumor growth in six mouse tumor models of non-Hodgkin lymphoma and multiple myeloma. The findings were presented Friday, September 16 at the 2016 American Society of Hematology Meeting on Hematologic Malignancies in Chicago.
“The findings demonstrate that CD74 is an ideal target for Sutro’s novel antibody drug conjugates and underscore how we’re accelerating ADC development using Sutro’s proprietary cell-free platform through the late preclinical phase and towards the clinic,” Sutro CEO Bill Newell said.
Sutro’s novel ADCs efficiently killed multiple myeloma, mantle cell lymphoma, diffuse large B-cell lymphoma and other Non-Hodgkin lymphoma cell lines in vitro. In vivo, these ADCs significantly reduced tumor growth in ANBL-6, CAG and ARP-1 multiple myeloma models and WSU-DLCL2, OCI-Ly10, SU-DHL-6 lymphoma models.
About Sutro Biopharma
Sutro Biopharma Inc. located in South San Francisco, develops best-in-class antibody drug conjugate (ADC) and multi-specific antibody-based therapeutics for cancer therapy, including immuno-oncology therapies. Sutro’s discovery and development efforts are driven by its proprietary Xpress CF™ and Xpress CF+™ platforms, a biochemical synthesis system that enables rapid and systematic evaluation of protein structure-activity relationships, as well as rapid and predictable scalability for manufacturing in Sutro’s cGMP facility. In addition to developing its own drug candidate pipeline, which is focused on mono- and bi-specific ADCs, Sutro is collaborating with select pharmaceutical and biotech companies to discover and develop novel therapeutics.